The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period.The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R spending & healthcare expenditure.
Emerging markets are expected to provide growth opportunities for players operating in the immunofluorescence assays market in the coming years.
However, quality concerns over antibodies are the major challenge in this market.To know about the assumptions considered for the study, Request for Free Sample Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=255585571The kits segment accounted for the highest growth rate in the Immunofluorescence assay market, by product, during the forecast periodThe Immunofluorescence assay market is segmented into reagents, instruments, antibodies, kits, and consumables and accessories.
The kits segment accounted for the highest growth rate in the Immunofluorescence assay market in 2020.
The demand for complete solutions from a single provider, like closed-system reagents with calibrated measurements of the required quantity of reagents and controls, among CROs, academic institutes, and research institutes is growing, contributing to this segment's high growth rate.Indirect immunofluorescence segment accounted for the highest CAGRBased on type, the immunofluorescence assays market is segmented into indirect immunofluorescence and direct immunofluorescence.
The major factors driving the growth of this segment are its advantages such as sensitivity, flexibility, better amplification of the signal, and lower cost over direct immunofluorescence.Cancer accounted for the largest share of the immunofluorescence assay market in 2020Based on disease, the immunofluorescence assays market is segmented into cancer, infectious diseases, autoimmune diseases, cardiovascular diseases, and other diseases.